Previous 10 | Next 10 |
Alector (NASDAQ: ALEC ) initiated with Buy rating and $44 (52% upside) price target at Stifel. More news on: Alector, Inc., Aridis Pharmaceuticals, Inc., BioLife Solutions, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Quick Take Passage Bio ( PASG ) intends to raise $126 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of genetic treatment candidates for monogenic (single gene pair) central nervous system [CNS] conditions. PASG has yet...
Gainers: vTv Therapeutics (NASDAQ: VTVT ) +57% . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...
The FDA designates Alector's ( ALEC +6.8% ) AL101 for Fast Track review for the treatment of patients with progranulin gene mutations causing frontotemporal dementia (FTD). More news on: Alector, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 for the treatment of ...
Quick Take Passage Bio ( PASG ) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement . The firm is developing genetic treatments for monogenic (single gene) central nervous system [CNS] health conditions. PASG is at pre-clinical stage...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its previously announced underwritten public offering of 9,602,500 shares of its common stock at th...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the underwriters fully exercised their option to purchase an additional 1,252,500 shares of common stock at t...
Alector (NASDAQ: ALEC ) slips 3% premarket on light volume in reaction to its public offering of 8.35M (from ~5.1M) common shares at $25/share. Gross proceeds should be ~$209M. More news on: Alector, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an upsized underwritten public offering of 8,350,000 shares of its common stock at a price of $25.0...
News, Short Squeeze, Breakout and More Instantly...
--INVOKE-2 is the first global Phas e 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative stud...
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company’s TREM2 and progranulin programs at the upcoming Alzheimer's Associatio...
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a corporate presentation at the H.C. Wainwright 5 th Annual Neuro Pers...